Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
      QxMD      Google Scholar   
Citation:
Blood vol 143 (16) 1616-1627
Year:
2024
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Long-Term-Followup
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
13
Parents:
3647  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, UG1CA189858, UG1CA233178, UG1CA233180, UG1CA233253, UG1CA232760, UG1CA233320, UG1CA233327, UG1CA233331, UG1CA233339; U10CA180863, CCS 707213 (CCTG), U10CA180820 (ECOG-ACRIN), U10CA180888 (SWOG)  
Corr. Author:
 
Authors:
                                                                 
Networks:
LAPS-IL036, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NC007, LAPS-NC010, LAPS-OH007, NY167, OH070, SCOR   
Study
Alliance-A041202
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Lymphoid Neoplasia